Literature DB >> 21555687

Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.

Sofie Van Binnebeek1, Christophe M Deroose, Kristof Baete, Christelle Terwinghe, Bert Vanbilloen, Michel Koole, Karin Haustermans, Luc Mortelmans, Chris Verslype, Eric Van Cutsem, Alfons Verbruggen, Felix M Mottaghy.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21555687     DOI： 10.1200/JCO.2010.34.3384

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Authors:  S Van Binnebeek; B Vanbilloen; K Baete; C Terwinghe; M Koole; F M Mottaghy; P M Clement; L Mortelmans; K Bogaerts; K Haustermans; K Nackaerts; E Van Cutsem; C Verslype; A Verbruggen; C M Deroose
Journal:  Eur Radiol       Date:  2015-07-12       Impact factor: 5.315

Review 2.  Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Authors:  Michael S Lee; Bert H O'Neil
Journal:  J Gastrointest Oncol       Date:  2016-10

3.  Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.

Authors:  Vincent Vandecaveye; Raphaëla C Dresen; Elin Pauwels; Sofie Van Binnebeek; Ragna Vanslembrouck; Kristof Baete; Felix M Mottaghy; Paul M Clement; Kristiaan Nackaerts; Eric Van Cutsem; Chris Verslype; Frederik De Keyzer; Christophe M Deroose
Journal:  Radiol Imaging Cancer       Date:  2022-05

4.  Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.

Authors:  Sofie Van Binnebeek; Kristof Baete; Bert Vanbilloen; Christelle Terwinghe; Michel Koole; Felix M Mottaghy; Paul M Clement; Luc Mortelmans; Karin Haustermans; Eric Van Cutsem; Alfons Verbruggen; Kris Bogaerts; Chris Verslype; Christophe M Deroose
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-26       Impact factor: 9.236

Review 5.  Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Authors:  Cassandra Miller; Julie Rousseau; Caterina F Ramogida; Anna Celler; Arman Rahmim; Carlos F Uribe
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.